The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
about
Pediatric Non-Alcoholic Fatty Liver DiseaseNAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.To screen or not to screen? Celiac antibodies in liver diseases.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.The future of diagnosing NASH - could a simple blood test be the key?Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.The pharmacological management of NAFLD in children and adolescents.Breaking fat: The regulation and mechanisms of lipophagy.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Emerging therapies for NASH - the future is now.The future of liver transplantation for viral hepatitis.Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis.PPARs and nonalcoholic fatty liver disease.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Liver macrophages in tissue homeostasis and disease.Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.Gastrointestinal Complications of Obesity.Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease.Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States.NAFLD: Is There Anything New under the Sun?Inflammation, mitochondrial metabolism and nutrition: the multi-faceted progression of non-alcoholic fatty liver disease to hepatocellular carcinomaMediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease.Increased Prevalence of NAFLD in IBD Patients.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population.In vitro cellular models of human hepatic fatty acid metabolism: differences between Huh7 and HepG2 cell lines in human and fetal bovine culturing serum.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis.Serum matrix metalloproteinase-1 level represents disease activity as opposed to fibrosis in patients with histologically proven nonalcoholic steatohepatitis.Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis.Clinical relevance of liver histopathology and different histological classifications of NASH in adults.Effects of melatonin on fatty liver disease: The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy.Current and future pharmacological therapies for NAFLD/NASH.Nonalcoholic Fatty Liver Disease Is a Susceptibility Factor for Perchloroethylene-Induced Liver Effects in Mice.A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.Steatosis caused by experimental periodontitis is reversible after removal of ligature in rats.Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease.Macrophages and lipid metabolism.
P2860
Q33831717-39264B23-AD9F-43ED-A8D2-99490373567BQ33844463-011B99D5-5B67-41B4-A54A-33D90F0A9F44Q34551744-40EDB66E-35A0-4434-A987-ED34CE86074FQ38627907-9E57446E-353B-4223-ACA7-F68DA94DAD0DQ38634380-DA2CDE1C-1617-4253-B7B7-185CEB88C25CQ38642356-A6D6C631-F61A-4023-A0F9-3C3AFF399EA1Q38643266-71EA102D-E67D-4A1A-AE9C-74A5B894A921Q38667805-43CF2B43-5D2B-4D4A-994E-8BEB780E9A90Q38737633-8B105488-700E-474F-82B5-13AFC3664C06Q38748157-E8A070A8-CEDA-4962-BF92-7885AC5E1C1AQ38774864-80CF026E-5A08-4E57-96D4-A9184DF7D2F5Q39021862-1947D08B-0218-45A3-85C2-23196F262208Q39029023-92237236-F57A-4543-A4BF-3022CD9EC181Q39183375-86A02973-438D-4E2A-8459-E0DE6E5382E0Q39187324-9AD33D92-2B27-4F58-A0E0-F874AFE34E7FQ40039094-9E4EEB8D-F4FE-42EB-B017-28F08AA70388Q40154406-11D85BBE-BF59-4E43-8FCD-A7A1FB916AD1Q40338492-0CE9D798-8FA0-49B2-8B55-370CD6AA5AF7Q41706840-755F486B-04E8-4A39-A265-557EB557C2D0Q41817046-7EF15FB5-1F3D-44D7-B351-619969C5F241Q41920894-6653D064-F4F3-4A15-939C-A18E2A5A5162Q42365749-DB898020-818A-4EA2-AA10-DFA9B903BCC5Q42380811-E15BE3EC-E869-4BC7-932B-CE809F1B790BQ44339679-612911E7-B414-499C-8849-21BFBF66ED2CQ45055950-85081C61-BC3A-4A02-A84F-328DF13640AFQ45067817-ACCCBA84-2A10-42A0-855B-0CE5541655A9Q45947181-DE9194FC-2D4B-49D8-B898-E223AF734982Q47116322-6F79E152-32A1-43C0-B6EC-94B102BB3438Q47136445-BDE2444E-BC25-4329-AF4B-7ECEDCE6E21DQ47368621-505D8183-E04C-4E20-B5D9-FCBEB478BDE1Q47389190-ACE4EC16-F0E7-438A-B4C2-F9A8A613EA24Q47559184-58E709FC-60E8-44B7-B057-F9214B1CECA5Q47581786-6F2E282D-DAD9-48BF-9CDA-D86E8BA91FE2Q47752889-7FF3E53B-82C6-405A-A63E-5018D778F193Q47778507-CE52C773-7320-454E-933F-FE6D18CDF2F7Q47951000-7973932B-4C27-4FD5-BA51-E6A34DE43FE4Q47966842-99B3BE2A-1747-423E-85E5-3395B6D66B1DQ48144949-0D3083B0-6565-401D-8A22-63A7B4E41F07Q48214770-694BC21A-7237-466A-A996-204CEADCB00BQ49026058-639225B9-6019-424D-92A7-15893E8244D7
P2860
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The economic and clinical burd ...... the United States and Europe.
@en
The economic and clinical burd ...... the United States and Europe.
@nl
type
label
The economic and clinical burd ...... the United States and Europe.
@en
The economic and clinical burd ...... the United States and Europe.
@nl
prefLabel
The economic and clinical burd ...... the United States and Europe.
@en
The economic and clinical burd ...... the United States and Europe.
@nl
P2093
P2860
P356
P1433
P1476
The economic and clinical burd ...... the United States and Europe.
@en
P2093
Andrei Racila
Deirdre Blissett
Linda Henry
Maria Stepanova
Rachel Beckerman
Robert Blissett
Sharon Hunt
Youssef Younossi
Zobair M Younossi
P2860
P304
P356
10.1002/HEP.28785
P407
P577
2016-08-20T00:00:00Z